Belenos Announces Positive Phase 1b Interim Asthma Results for BEL512, a Long-Acting TSLP/IL-13 Bispecific Antibody
BEL512 continues to demonstrate a favorable safety and tolerability profile, with adverse events balanced between treatment and placebo arms
By Day 4 BEL512 produced rapid and deep reductions in FeNO of approximately a 48% change from baseline, and achieved sustained reductions with a mean decrease of 46 ppb by Week 8, a -65% change from baseline
BEL512 produced rapid reductions in blood eosinophils, reaching levels approximately 26% lower than PBO at Day 4, and 50% lower than PBO by Week 5
Clinically meaningful improvements among patients with moderate asthma in pre-bronchodilator FEV1 compared with placebo were observed, reaching 181 ml placebo-adjusted mean change from baseline by Day 4, and 330 ml placebo-adjusted mean change from baseline by Week 7
